MENLO PARK, Calif., Aug. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com. Webcast replays will be available for at least 30 days following the event.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our existing HiFi long-read sequencing technology and our emerging short-read Sequencing by Binding (SBB™) technology. Our products address solutions across a broad set of applications, including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for research use only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
650.521.8450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Lizelda Lopez
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.97 |
| Daily Change: | 0.04 2.07 |
| Daily Volume: | 10,085,098 |
| Market Cap: | US$579.810M |
November 07, 2024 November 06, 2024 October 30, 2024 October 29, 2024 October 22, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
